1. Home
  2. HSPO vs QNCX Comparison

HSPO vs QNCX Comparison

Compare HSPO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • QNCX
  • Stock Information
  • Founded
  • HSPO 2014
  • QNCX 2012
  • Country
  • HSPO United States
  • QNCX United States
  • Employees
  • HSPO N/A
  • QNCX N/A
  • Industry
  • HSPO Blank Checks
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HSPO Finance
  • QNCX Health Care
  • Exchange
  • HSPO Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • HSPO 92.0M
  • QNCX 62.0M
  • IPO Year
  • HSPO 2022
  • QNCX 2019
  • Fundamental
  • Price
  • HSPO $11.69
  • QNCX $1.41
  • Analyst Decision
  • HSPO
  • QNCX Strong Buy
  • Analyst Count
  • HSPO 0
  • QNCX 4
  • Target Price
  • HSPO N/A
  • QNCX $9.50
  • AVG Volume (30 Days)
  • HSPO 3.5K
  • QNCX 121.0K
  • Earning Date
  • HSPO 01-01-0001
  • QNCX 03-31-2025
  • Dividend Yield
  • HSPO N/A
  • QNCX N/A
  • EPS Growth
  • HSPO 2.63
  • QNCX N/A
  • EPS
  • HSPO 0.28
  • QNCX N/A
  • Revenue
  • HSPO N/A
  • QNCX N/A
  • Revenue This Year
  • HSPO N/A
  • QNCX N/A
  • Revenue Next Year
  • HSPO N/A
  • QNCX N/A
  • P/E Ratio
  • HSPO $41.53
  • QNCX N/A
  • Revenue Growth
  • HSPO N/A
  • QNCX N/A
  • 52 Week Low
  • HSPO $10.80
  • QNCX $0.51
  • 52 Week High
  • HSPO $12.41
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 51.52
  • QNCX 37.41
  • Support Level
  • HSPO $11.70
  • QNCX $1.38
  • Resistance Level
  • HSPO $11.89
  • QNCX $1.49
  • Average True Range (ATR)
  • HSPO 0.07
  • QNCX 0.11
  • MACD
  • HSPO -0.02
  • QNCX -0.01
  • Stochastic Oscillator
  • HSPO 2.38
  • QNCX 12.50

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Share on Social Networks: